Clinical Trials Browser

Triple Negative Breast Neoplasms × irinotecan sucrosofate × Clear all

NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase 2 Withdrawn

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Phase 1 Completed

45 enrolled 33 charts

BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms